How is Menveo supplied?
One dose of Menveo consists of 2 vials: one containing MenA lyophilized conjugate component and the other containing MenCYW-135 liquid conjugate component for reconstitution. There are 5 doses (a total of 10 vials) in each package of Menveo.1 Indication and Important Safety Information Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections. Menveo is contraindicated in individuals who have experienced a severe allergic reaction after a previous dose of Menveo, any component of this vaccine, or any other CRM197-, diphtheria toxoid-, or meningococcal-containing vaccine. Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of Menveo. Vaccinees may develop syncope, someti